Latest news

• Vertex’s triple combination CF therapy to become available on the NHS

  Although the European licence for Kaftrio, named Trikafta in the US, only covers patients aged 12 years and older, younger children and those over 12 years of age who are not

• Vertex, NHS England and NICE finally reach agreement for Orkambi

  Also, with news that the new triple therapy, Trikafta, which 90% of people with cystic fibrosis could stand to benefit from, could be licenced for use in the coming year, we

• Vertex scores FDA approval for CF triple therapy Trikafta

  Decision comes only a few months after therapy was filed. Vertex has scored an earlier than expected FDA approval of its cystic fibrosis triple therapy Trikafta, and has priced it at ... Trikafta is priced similarly to Kalydeco – Vertex and NHS